Interleukin-2 Transiently Inhibits Pulsatile Growth Hormone Secretion in Young but not Older Healthy Men

J Clin Endocrinol Metab. 2021 Sep 27;106(10):2855-2864. doi: 10.1210/clinem/dgab484.

Abstract

Context: Interleukin-2 (IL-2), a proinflammatory cytokine, has been used to treat malignancies. Increased cortisol and adrenocorticotropin (ACTH) were noted, but growth hormone (GH) secretion was not investigated in detail.

Objective: We quantified GH secretion after a single subcutaneous injection of IL-2 in 17 young and 18 older healthy men in relation to dose, age, and body composition.

Methods: This was a placebo-controlled, blinded, prospectively randomized, crossover study. At 20:00 hours IL-2 (3 or 6 million units/m2) or saline was injected subcutaneously. Lights were off between 23:00 and 07:00 hours. Blood was sampled at 10-minute intervals for 24 hours. Outcome measures included convolution analysis of GH secretion.

Results: GH profiles were pulsatile under both experimental conditions and lower in older than young volunteers. Since the effect of IL-2 might be time limited, GH analyses were performed on the complete 24-hour series and the 6 hours after IL-2 administration. Total and pulsatile 24-hour GH secretion decreased nonsignificantly. Pulsatile secretion fell over the first 6 hours after IL-2 (P = .03), with visceral fat as a covariate (P = .003), but not age (P = .10). Plots of cumulative 2-hour bins of GH pulse mass showed a distinction by treatment and age groups: A temporary GH decrease of 32% and 28% occurred in the first 2-hour bins after midnight (P = .02 and .04) in young participants, whereas in older individuals no differences were present at any time point.

Conclusion: This study demonstrates that IL-2 temporarily diminishes GH secretion in young, but not older, men.

Keywords: cytokines; growth hormone; inflammation; interleukin.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Age Factors*
  • Aged
  • Aged, 80 and over
  • Cross-Over Studies
  • Double-Blind Method
  • Growth Hormone / drug effects*
  • Healthy Volunteers
  • Humans
  • Injections, Subcutaneous
  • Interleukin-2 / pharmacology*
  • Male
  • Middle Aged
  • Prospective Studies
  • Secretory Pathway / drug effects*
  • Time Factors*
  • Young Adult

Substances

  • Interleukin-2
  • Growth Hormone